A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: Evaluation of insulin-like growth factor suppression and chemotherapy

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2406-2412

  Khanna, Chand ^a   Prehn, Jennifer ^a   Hayden, David ^b   Cassaday, Ryan D ^a   Caylor, Jana ^a   Jacob, Shevin ^a   Bose, Seuli M ^a   Hong, Sung Hyeok ^a   Hewitt, Stephen M ^a   Helman, Lee J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; OCTREOTIDE; SOMATOMEDIN C; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DOG; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION; TUMOR NECROSIS; ANIMAL; BLOOD; BONE TUMOR; CELL DIVISION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; FEMALE; FOLLOW UP; GENETICS; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; RANDOMIZATION; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE NEOPLASMS; CARBOPLATIN; CELL DIVISION; COMPARATIVE STUDY; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; FOLLOW-UP STUDIES; INSULIN-LIKE GROWTH FACTOR I; MALE; MAXIMUM TOLERATED DOSE; OCTREOTIDE; OSTEOSARCOMA; RANDOM ALLOCATION; SURVIVAL RATE; TREATMENT OUTCOME; ANIMALS;

EID: 0035992429     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Osteosarcoma
2. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy
3. Treatment of metastatic osteosarcoma at diagnosis: A Pediatric Oncology Group Study
4. The insulin-like growth factor I receptor: A key to tumor growth?
5. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth
6. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo
7. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy
8. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone
9. Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice
10. Oncological applications of somatostatin analogues
11. The insulin like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis
12. The effect of somatostatin analogue on glucose homeostasis in conscious dogs
13. Treatment of metastatic osteosarcoma with somatostatin analogue OncoLAR: Significant reduction of IGF-I serum levels
14. Insulin-like growth factor-I inhibits the progression of human U-2 OS osteosarcoma cells towards programmed cell death through interaction with the IGF-I receptor
15. Spontaneously occurring tumors of companion animals as models for human cancer
16. Comparative aspects of osteosarcoma. Dog versus man
17. Methods of Randomization
18. Tissue microarrays for high-throughput molecular profiling of tumor specimens
19. Normal growth and development in the absence of hepatic insulin-like growth factor I
20. The receptor for the type 1 insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis